NCT02313012 is a Phase 1 clinical trial of CC-90003 in Neoplasm Metastasis, sponsored by Celgene.

Who is sponsoring NCT02313012?

NCT02313012 is sponsored by Celgene.

What drugs are being tested in NCT02313012?

Interventions in NCT02313012: CC-90003.

What condition does NCT02313012 study?

NCT02313012 studies Neoplasm Metastasis.

Is NCT02313012 still recruiting?

NCT02313012 is currently terminated. Last updated 18 November 2019.

Last reviewed 2019-11-18 · How we verify

NCT02313012

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Terminated Phase 1 Last updated 18 November 2019

What this trial tests

Phase 1 trial testing CC-90003 in Neoplasm Metastasis in 19 participants. Terminated before completion.

Timeline

5 January 2015

Primary endpoint
3 May 2016

3 May 2016

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	5 January 2015
Primary completion	3 May 2016
Estimated completion	3 May 2016
Sites	5 locations across United States, Australia

Drugs / interventions tested

CC-90003 — full drug profile →

Conditions studied

Neoplasm Metastasis — all drugs for Neoplasm Metastasis →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Neoplasm Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The CC-90003-ST -001 trial is a first-in-man, open-label study in subjects with locally-advanced or wide spread cancers to determine if CC-90003 (an oral medication) can be adequately tolerated with minimal side effects.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Strategies to tackle RAS-mutated metastatic colorectal cancer.
Patelli G, Tosi F, Amatu A, Mauri G, et al · · 2021 · cited 65× · PMID 34044286 · DOI 10.1016/j.esmoop.2021.100156
Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy.
Pan X, Pei J, Wang A, Shuai W, et al · · 2022 · cited 49× · PMID 35646548 · DOI 10.1016/j.apsb.2021.12.022
Precision drugging of the MAPK pathway in head and neck cancer.
Ngan HL, Law CH, Choi YCY, Chan JY, et al · · 2022 · cited 43× · PMID 35296678 · DOI 10.1038/s41525-022-00293-1
Natural products targeting the MAPK-signaling pathway in cancer: overview.
Shi A, Liu L, Li S, Qi B. · · 2024 · cited 40× · PMID 38193944 · DOI 10.1007/s00432-023-05572-7
MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.
Tran KA, Cheng MY, Mitra A, Ogawa H, et al · · 2016 · cited 32× · PMID 26730180 · DOI 10.2147/dddt.s93545
Targeting ERK beyond the boundaries of the kinase active site in melanoma.
Sammons RM, Ghose R, Tsai KY, Dalby KN. · · 2019 · cited 29× · PMID 31190430 · DOI 10.1002/mc.23047
Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer.
Graham DM, Coyle VM, Kennedy RD, Wilson RH. · · 2016 · cited 27× · PMID 27340376 · DOI 10.1007/s11888-016-0312-y
Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet.
McArthur GA. · · 2015 · cited 26× · PMID 26236691 · DOI 10.3389/fonc.2015.00161

Verify or expand the search:

Other recruiting trials for Neoplasm Metastasis

Currently open trials in the same condition.

NCT06912087 — Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC · Phase 1 · recruiting
NCT06534580 — Virtual Reality for Advanced Cancer Pain · active not recruiting
NCT06460961 — A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-68 · Phase 1 · active not recruiting
NCT05573893 — PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Dat · recruiting
NCT06046131 — Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. · NA · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02313012 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 18 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02313012.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing